Arpraziquantel : Society and culture, Further reading Wikipedia, the free encyclopedia

Arpraziquantel

Medication

P02BA03 (WHO)

IdentifiersCAS Number

57452-98-9

PubChem CID

445900

DrugBank

DB11749

ChemSpider

393394

UNII

WF15T5925V

KEGG

D12741

ChEMBL

ChEMBL1235551

PDB ligand

PZQ (PDBe, RCSB PDB)

CompTox Dashboard (EPA)

DTXSID80904739

Chemical and physical dataFormulaC₁₉H₂₄N₂O₂Molar mass312.413 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

[H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1

InChI

InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1
Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N

Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, a medication which is under investigation for the treatment of schistosomiasis in young children with less side effects than the racemate.^[1]

Society and culture

Legal status

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.^[1] The applicant for this medicinal product is Merck Europe B.V.^[1] It is intended exclusively for markets outside the European Union.^[1]

Names

Arpraziquantel is the International nonproprietary name.^[2]

References

^ ^a ^b ^c ^d "Arpraziquantel". European Medicines Agency. 14 December 2023. Archived from the original on 20 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

Zdesenko G, Mutapi F (September 2020). "Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models". PLOS Neglected Tropical Diseases. 14 (9): e0008649. doi:10.1371/journal.pntd.0008649. PMC 7518612. PMID 32976496.

Antiparasitics – Anthelmintics (P02) and endectocides (QP54)

Antiplatyhelmintic agents

Antitrematodals
(schistosomicides)

Binds tubulin	benzimidazole Triclabendazole^#
AChE inhibitor	phosphonic acid Metrifonate^‡
Other/unknown	quinoline Arpraziquantel Praziquantel^# Oxamniquine^# phenol Bithionol thiazole Niridazole thioxanthone Hycanthone Lucanthone antimony compounds Stibophen Tartar emetic^‡

Anticestodals
(taeniacides)

Binds tubulin	benzimidazole Albendazole^#
Other/unknown	quinoline Praziquantel^# salicylanilide Niclosamide^# aminoacridine Quinacrine butyrophenone Desaspidin chlorophenol Dichlorophen

Antinematodal agents
(including
macrofilaricides)

Binds tubulin	benzimidazole Mebendazole^# Albendazole^# Tiabendazole Fenbendazole Ciclobendazole Flubendazole
Glutamate-gated chloride channel, GABA receptor	avermectins Abamectin Doramectin Emamectin Eprinomectin Ivermectin^# Selamectin milbemycins Moxidectin Milbemycin oxime
NMDA	tetrahydropyrimidine Pyrantel^# pyrantel pamoate Oxantel Morantel Carbantel Febantel (aka felsantel)
Other/unknown	piperazine Piperazine Diethylcarbamazine^# thiazole Levamisole^# quinolinium Pyrvinium benzylammonium Bephenium naphthalenesulfonate Suramin^# Ascaridole^‡ Hexylresorcinol Santonin^‡ Tribendimidine Tetrachloroethylene^‡